CN1190228C - Angong hemostatics - Google Patents
Angong hemostatics Download PDFInfo
- Publication number
- CN1190228C CN1190228C CN 03117966 CN03117966A CN1190228C CN 1190228 C CN1190228 C CN 1190228C CN 03117966 CN03117966 CN 03117966 CN 03117966 A CN03117966 A CN 03117966A CN 1190228 C CN1190228 C CN 1190228C
- Authority
- CN
- China
- Prior art keywords
- medicine
- group
- blood
- weight portions
- peace
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides a medicine for treating metrorrhagia, which is composed of 750 to 2500 weight portions of motherwort herb, 167 to 833 weight portions of notoginseng, 333 to 1667 weight portions of charred schizonepeta and 333 to 1667 weight portions of amber. The medicine has the efficacy of promoting blood circulation, relieving blood stasis, regulating menstruation and hemostasis, and mainly treats postpartum continuous disease symptoms, metrorrhagia and menoxenia. The medicine has wide range of application and is suitable for treating uterus subinvolution after term birth and abortion, induced abortion, medical abortion, irregular vagina bleeding caused by an intrauterine contraceptive device and dysfunctional uterine bleeding.
Description
Technical field:
The present invention is relevant with hemorrhage, and is relevant with peace palace haemostatic medicament especially.
Background technology:
It is main clinical manifestation not to the utmost that prolonged lochia claims " postpartum lochiorrhea ", " lochia is more than " to surpass for 3 weeks still dripping with lochia again, and waits other General Symptoms with stomachache.This disease is similar to modern medicine alleged " subinvolution of uterus ".In clinical, often residual because of part Placenta Hominis, fetal membrane, or cause this disease because of factors such as endometritis, myometritis or pelvic infections.In the treatment, give uterotonic to promote uterine contraction, be extremely common illness in puerperal more.In recent years, along with the extensive and persistent of China's family planning work carried out, the irregular sickness rate of bleeding of vagina that causes because of artificial abortion is more and more higher.Modern research and treatment about this disease are mostly on traditional prescription, with the card plus-minus.Big Xing Shi treats prolonged lochia 34 examples with peace towards soup as the palace, and 24 examples are only taken medicine 3 doses of blood as a result, and 10 examples are only taken medicine 6～9 doses of blood; Usefulness silver yellow soup such as Tanaka is upright are treated this disease 62 examples, and Zheng Jiaben adds Hirudo treatment postpartum lochiorrhea with TAOHONG SIWU TANG, has all obtained comparatively satisfied effect.Relevant Chinese patent medicine is to the treatment of this disease, and is the most common with motherwort formulation, as Herba Leonuri paste, oral liquid, electuary, capsule etc.
Summary of the invention:
The objective of the invention is to have no side effect in order to provide a kind of, blood circulation promoting and blood stasis dispelling, regulating menstruation, hemostasis cures mainly prolonged lochia, and effects such as metrorrhagia, menoxenia are good, peace palace haemostatic medicament applied widely.
The object of the present invention is achieved like this:
The present invention pacifies the palace haemostatic medicament, is made by following raw material by weight:
Herba Leonuri 750～2500
Radix Notoginseng 167～833
Herba Schizonepetae charcoal 333～1667
Succinum 333～1667.
Above-mentioned medicine is made by following raw material by weight:
Herba Leonuri 1500
Radix Notoginseng 250
Herba Schizonepetae charcoal 500
Succinum 500, therapeutic effect is better.
Monarch drug in the Herba Leonuri side of being in the medicine of the present invention, mainly contain ice dissolubility alkaloid stachydrine, leonurine etc., the Herba Leonuri pungent drugs can disperse and bitter drugs can descend, effect with promoting tissue regeneration by removing blood stasis, to medicine first choice of treatment gynecological Blood stasis, be usually used in treating the menoxenia due to the blood vessels retardance, diseases such as postpartum hemorrhage, puerperal abdonimal pain; Radix Notoginseng contains the merit that saponin, volatile oil, flavone, polysaccharide, aminoacid etc. have hemostasis, dissipating blood stasis analgesic therapy, with Herba Leonuri with just not decreasing it with then loosing blood, stop blooding and the fraud of the unfounded stasis of blood, and the merit of tool analgesic therapy, so the stomachache due to can main blood stasis is the ministerial drug in the side of being; Herba Schizonepetae contains volatile oil, flavone etc., the present invention with its parch to black after processed product, i.e. Herba Schizonepetae charcoal, volatile oil component volatilizees.The light thing of its property of Herba Schizonepetae, the stove charcoal is then gone into blood system, with assistant Radix Notoginseng treating blood disorders hemostasis; Succinum is the prolonged Hydrocarbon that condenses and form under the resin burial ground of pinaceae plant in ancient times, resinous, volatile oil.Succinum composes oneself to pacify and shies, promoting blood circulation to remove blood stasis, and treatment blood stasis pain in puerperal is with the same effect that can help its diffusing blood and relieving pain of Radix Notoginseng.Four Chinese medicine thing of the present invention, compatibility is precise and appropriate, close promoting tissue regeneration by removing blood stasis altogether, draw blood return through usefulness, so can receive the effect of treatment blood stasis type prolonged lochia.
Medicine of the present invention can be made into granule, capsule or other dosage form.
When preparing this medicine, Radix Notoginseng, succinum pulverize separately are become fine powder, Herba Leonuri, Herba Schizonepetae charcoal are soaked.Decoct, filter, medicinal residues decoct with water secondary at least again, filter, and merging filtrate is concentrated into clear paste, and adding ethanol is 50% to containing the alcohol amount, stirs evenly, and leaves standstill transition, filter, and filtrate recycling ethanol, and be condensed into clear paste.Add Radix Notoginseng, succinum fine powder and right amount of auxiliary materials, mixing is made granule, drying, and packing promptly gets pacifies the palace hemostasis granules.To pacify the palace hemostasis granules and be used for clinical and experimentation, the I clinical trial phase shows, said preparation to postpartum subinvolution of uterus and artificial abortion after vaginal hemorrhage all have notable therapeutic effect, and do not find any toxicity and ill effect.Pharmacological testing shows that said preparation can obviously shorten clotting time and the bleeding time of mice; And blood plasma recalcification time and the prothrombin time of rat; Can improve the tension force that uterine smooth muscle shrinks; Rat " blood stasis " due to epinephrine+frozen water stimulation is demonstrate,proved, and high dose group can reduce whole blood contrast viscosity, plasma viscosity and the packed cell volume that model group raises, and illustrates that it has certain function of promoting blood circulation to disperse blood clots.Acute and long term toxicity test shows that said preparation does not have obvious toxic and side effects (seeing Table 1～table 15).
Table 1 peace palace hemostasis granules is to the influence of clotting time of mice (X ± S)
Group dosage number of animals clotting time
(gkg
-1) (only) (min)
Normal control group equivalent NS 15 1.57 ± 0.25
YUNNAN BAIYAO group 0.7 15 0.93 ± 0.33**
Peace palace hemostasis granules 4 15 1.02 ± 0.24**
Peace palace hemostasis granules 2 15 1.24 ± 0.40*
Annotate: compare with the normal control group: * P＜0.05, * * P＜0.01
Table 2 peace palace hemostasis granules is to the influence in mice bleeding time (X ± S)
Group dosage number of animals clotting time
(gkg
-1) (only) (min)
Normal control group equivalent NS 14 14.52 ± 3.31
YUNNAN BAIYAO group 0.7 14 10.58 ± 1.60**
Peace palace hemostasis granules 4 14 11.17 ± 1.89**
Peace palace hemostasis granules 2 14 13.01 ± 1.25*
Annotate: compare with the normal control group: * P＜0.05, * * P＜0.01
Table 3 peace palace hemostasis granules is to the influence of rat plasma recalcification time (X ± S)
Dosage number of animals blood plasma recalcification time (second)
Group
(gkg
-1) (only) PRP PPP
Normal control group equivalent NS 8 115.7 ± 9.2 120.8 ± 11.0
YUNNAN BAIYAO group 0.6 8 90.4 ± 6.5** 110.5 ± 8.4*
Hemostasis granules 3.6 8 88.6 ± 5.3** 102.1 ± 9.6**
1.8 8 97.2±8.9** 100.7±10.5**
0.9 8 108.1±4.6* 114.3±9.2
Annotate: compare with normal group: * P＜0.05, * * P＜0.01
Therefore peace palace hemostasis granules and YUNNAN BAIYAO all can make the blood plasma recalcification time shorten (comprising PRP and PPP), illustrate that they have facilitation to the endogenous coagulation pathway.
Table 4 peace palace hemostasis granules is to the influence of rat plasma prothrombin time (X ± S)
Group dosage number of animals plasma prothrombin time P value
(gkg
-1) (only) (S)
Normal control equivalent NS 8 12.53 ± 1.14
YUNNAN BAIYAO 0.6 8 10.27 ± 1.35＜0.01
Hemostasis granules 3.6 8 9.01 ± 1.03＜0.01
1.8 8 11.45±0.86 ＞0.05
0.9 8 12.40±0.90 ＞0.05
Shown in the table 4, shortening is all arranged, act on similarly, and dose-effect relationship is arranged to YUNNAN BAIYAO with plasma prothrombin time behind the peace palace hemostasis granules.Point out it that exogenous cruor pathway is had facilitation.
Table 5 peace palace hemostasis granules is to the influence of rat blood serum FDP (X ± S)
Group dosage number of animals FDP amount P value
(gkg
-1) (only) (μ g/ml)
Normal control equivalent NS 8 5.43 ± 1.11＜0.05
YUNNAN BAIYAO 0.6 8 4.60 ± 1.34＜0.05
Hemostasis granules 3.6 8 4.81 ± 1.82＜0.05
1.8 8 4.75±0.40 ＞0.05
0.9 5.02±1.01
Last table shows that peace palace hemostasis granules is the same with YUNNAN BAIYAO, and levels of fdp content is reduced, but compares no difference of science of statistics with the normal control group, points out them the fibrinolytic process to be had the trend of inhibition.
Table 6 peace palace hemostasis granules to the influence of normal isolated rat uterine contraction activity (X ± s, n=6)
| (money time/10min) is behind tension force (mm) amplitude (mm) medicine (mg/ml) the medicine prodrug behind the medicine prodrug behind the medicine prodrug for the final concentration frequency |
| 2.0 6.6 ± 1.1 6.6 ± 0.8 0 ± 0 0.8 ± 0.6* 5.1 ± 1.5 7.7 ± 2.4* particle 4.0 6.5 ± 1.0 6.3 ± 0.8 0 ± 0 1.6 ± 0.9* 5.0 ± 1.6 5.2 ± 1.8 8.0 6.5 ± 1.2 6.2 ± 0.5 0 ± 0 1.2 ± 0.7* 5.3 ± 1.7 4.6 ± 1.3 of stopping blooding, Normal group equivalent nutrient solution 6.8 ± 1.2 6.7 ± 0.9 0 ± 0 0.1 ± 0.1 5.3 ± 1.4 5.4 ± 1.3 Yunnan Baiyao 0.12 6.5 ± 1.2 6.9 ± 1.3 0 ± 0 1.5 ± 0.5* 5.2 ± 1.4 7.7 ± 2.3* 0.24 6.6 ± 1.1 7.2 ± 1.4 0 ± 0 1.9 ± 0.6** 5.1 ± 1.6 8.2 ± 2.5* peace palace |
The uterine contraction baseline is designated as 0 (being that tension force is 0) before annotating (1) administration.(2) with before the medicine compare * P＜0.05, * * P＜0.1.
As seen table 6 is pacified palace hemostasis granules various dose and can significantly be increased the uterotonic tension force of isolated rat, and only low dosage increases shrinkage amplitude, then influences not obvious to contraction frequency.
Table 8 peace palace hemostasis granules to female rats sexual organ and gonadal hormone (X ± s, n=8)
The heavy ovary in group dosage uterus weighs estradiol season ketone
(g/kg) (mg/g body weight) (mg/g) Pmol/L (mmol/L)
Normal control equivalent NS 2.55 ± 0.90 0.47 ± 0.18 56.24 ± 1.807 83.00 ± 24.15
YUNNAN BAIYAO 0.6 2.26 ± 1.25 0.56 ± 0.13 72.18 ± 24.90 78.65 ± 20.06
Hemostasis granules 3.6 2.60 ± 0.81 0.5 ± 0.20 78.35 ± 23.16 75.91 ± 21.82
The peace palace stops blooding 1.8 2.73 ± 1.06 0.49 ± 0.15 60.40 ± 21.41 81.23 ± 21.82
Table 8 shows that peace palace hemostasis granules does not have obvious influence to the uterus and the ovary weight of female rats, and the estradiol level of high dose group is the same with YUNNAN BAIYAO, and rising trend is arranged, but no difference of science of statistics does not then have obvious influence to progesterone level.
Table 9 peace palace hemostasis granules to the influence of " blood stasis " card rat serum rheological characteristic (X ± s, n=6)
Final concentration whole blood contrast viscosity plasma viscosity packed cell volume erythrocyte electrophoresis
Group
(mg/ml) height is cut low cutting (ratio) (%) time (S)
Normal control equivalent NS 6.31 ± 0.54 9.47 ± 1.20 1.60 ± 0.11 40.3 ± 0.68 19.13 ± 0.80
Model group NS 9.15 ± 1.5
The Δ Δ13.26 ± 2.18
The Δ Δ2.15 ± 0.30
The Δ Δ44.0 ± 2.45
The Δ Δ18.16 ± 0.96
YUNNAN BAIYAO 0.6 7.85 ± 0.84* 11.31 ± 1.74* 1.76 ± 0.15* 41.6 ± 1.24* 17.85 ± 1.83
Hemostasis granules 3.6 8.04 ± 0.90* 11.63 ± 1.80* 1.62 ± 0.20* 42.5 ± 1.10* 19.50 ± 0.87
1.8 8.36±0.78 12.45±1.62 1.90±0.24 44.7±2.75 19.02±1.04
Annotate: compare Δ P＜0.05, Δ Δ P＜0.01 with normal group; Compare * P＜0.05 with model group.
Therefore, can cause rat " blood stasis " card with epinephrine+frozen water stimulation, whole blood contrast viscosity, plasma viscosity and packed cell volume are increased.The high dose group of peace palace hemostasis granules is the same with YUNNAN BAIYAO, and whole blood contrast viscosity, plasma viscosity and packed cell volume that " blood stasis " card rat is raise reduce, and its low dose group effect is not obvious, shows that peace palace hemostasis granules has certain function of promoting blood circulation to disperse blood clots.
From table 1～table 9 as can be known, peace palace hemostasis granules can shorten clotting time and the bleeding time of mice; Obviously shorten rat plasma recalcification time and prothrombin time, the former reflects endogenous blood coagulation system, the latter is reflected extrinsic coagulation system, and the fibrinolytic protein catabolite is not had obvious influence, illustrates that the generation of its Blood clotting has certain relation with promoting endogenous and extrinsic coagulation process.
Test shows in the body uterus for isolated rat uterus and rabbit, and used dosage mainly improves the tension force that the flat bone flesh of rat uterus shrinks, and secondly is shrinkage amplitude, and frequency is not then had obvious influence.These effects cure mainly the metrorrhagia and metrostaxis in puerperal with it, and lochiorrhea is consistent.
Female rats sexual organ and gonadal hormone test show that the short-term administration does not have obvious influence to the weight of uterus and ovary, though estradiol level has rising trend, not statistically significant comprises that progesterone does not have tangible effect at the Nei Angong hemostasis granules.
" blood stasis " card rat due to epinephrine+frozen water stimulated, high dose group can reduce whole blood contrast viscosity, plasma viscosity and the packed cell volume that model group raises, and illustrates that it has certain function of promoting blood circulation to disperse blood clots.
Table 10 peace palace hemostasis granules is to the influence (X ± S, g/ are only) of rat body weight
| All high dose group low dose group matched groups |
| 0 190.7±9.6 193.5±6.3 191.4±8.1 1 207.3±10.2 208.4±7.9 210.1±10.5 2 219.4±11.0 222.7±13.8 221.3±9.4 3 235.0±8.5 234.3±12.0 236.5±13.7 4 248.5±14.3 249.6±9.1 250.0±12.8 5 260.2±17.5 264.5±13.2 262.6±15.0 6 274.6±16.9 278.8±18.4 277.2±19.6 |
Annotate: (1) 1～4 week was the administration phase, and 5～6 weeks were convalescent period;
(2) medication group and matched group be P＞0.05 relatively.
Table 11 peace palace hemostasis granules is learned the influence (X ± S) of index to rat blood
| Index REC Hb BPC WEC DC CT group (10 12/L) (g/L) (10 9/L) (10 9/ L) N (%) L (1%) (second) |
| After administration 4 week after (n=2) control group 5.31 ± 0.21 154.4 ± 3.4 311.7 ± 11.5 5.80 ± 0.87 30.5 ± 1.8 70.2 ± 1.4 85.5 ± 20.0 high dose group 5.10 ± 0.24 152.0 ± 5.3 309.3 ± 10.3 6.16 ± 0.72 32.1 ± 2.1 67.3 ± 1.8**, 64.2 ± 17.5** low dose group, 5.31 ± 0.23 150.6 ± 7.5* 313.2 ± 12.0 6.03 ± 0.72 29.2 ± 1.3 69.6 ± 1.56 70.1 ± 23.4 drug withdrawals 2 weeks (n=2) control group 5.18 ± 0.18 152.3 ± 3.9 313.0 ± 18.1 6.01 ± 0.78 28.3 ± 3.0 21.5 ± 2.1 80.3 ± 28.6 high dose group 5.10 ± 0.17 153.6 ± 4.0 315.3 ± 11.8 6.40 ± 0.59 27.5 ± 2.8 72.0 ± 2.8 82.4 ± 29.3 low dose group 5.06 ± 0.15 152.6 ± 6.1 320.7 ± 12.0 6.38 ± 0.74 29.3 ± 2.5 70.4 ± 3.2 78.0 ± 16.2 |
Annotate: compare * P＜0.05 with matched group.
Table 12 peace palace hemostasis granules is to the influence of rats'liver function (X ± S)
Index ALT AST ALP TP ALB T-BIL
Group (μ) is (μ) (μ) (g/L) (μ mol/L) (μ)
4 weeks of administration
Back (n=12)
Matched group 13.25 ± 3.74 11.32 ± 2.95 10.81 ± 1.32 78.55 ± 2.67 48.00 ± 2.83 4.75 ± 0.36
High dose group 12.60 ± 4.02 12.18 ± 2.42 9.66 ± 1.23 76.90 ± 3.01 47.03 ± 3.54 4.39 ± 0.50
Low dose group 15.16 ± 2.61 10.66 ± 2.90 9.58 ± 1.08 75.67 ± 6.04* 45.10 ± 5.51 4.50 ± 0.64
After the drug withdrawal 2
Week (n=8)
Matched group 11.37 ± 2.13 9.00 ± 3.64 8.25 ± 1.28 76.75 ± 3.90 41.31 ± 4.34 6.53 ± 0.79
High dose group 10.87 ± 2.23 8.00 ± 1.30 7.25 ± 1.26 76.25 ± 4.73 44.50 ± 6.39 5.96 ± 0.91
Low dose group 11.50 ± 2.92 9.75 ± 1.90 8.75 ± 1.60 78.50 ± 26.70 44.37 ± 4.56 5.71 ± 0.28
Annotate: compare * P＜0.05 with matched group.
The influence that table 13 peace palace hemostasis granules refers to rat function and blood glucose, blood
Index BUN Crea GLU TG TCHO
(mmol/L) (g/L) (mmol/L) for group (mmol/L) (μ mol/L)
4 weeks of administration
Back (n=2)
Matched group 4.48 ± 0.44 86.06 ± 6.44 5.80 ± 0.87 0.99 ± 0.16 5.13 ± 0.69
High dose group 5.15 ± 0.56 85.45 ± 7.20 5.21 ± 0.56 1.06 ± 0.14 5.00 ± 0.56
Low dose group 5.09 ± 0.66 83.50 ± 7.46 4.97 ± 0.55 1.07 ± 0.17 4.97 ± 0.55
After the drug withdrawal 2
Week (n=2)
Matched group 5.36 ± 0.51 80.87 ± 5.27 5.28 ± 0.26 1.04 ± 0.12 4.91 ± 0.58
High dose group 5.47 ± 0.59 68.87 ± 25.31 5.17 ± 0.50 1.11 ± 0.07 4.16 ± 0.37
Low dose group 5.16 ± 0.52 74.12 ± 5.05 5.26 ± 0.28 1.13 ± 0.11 5.41 ± 0.46
Annotate: compare * P＜0.05 with matched group.
Table 14 peace palace hemostasis granules is to the influence of Rats Organs and Tissues coefficient (mg/g, X ± S)
| Internal organs time matched group high dose group low dose group |
| 4.19±0.40 4.06±0.76 4.25±0.68 3.19±0.42 3.58±0.19 3.24±0.28 31.902.90 28.72±2.71 31.60±3.87 27.97±2.63 30.20±3.68 28.70±1.21 4.90±1.02 4.39±0.91 5.43±2.27 3.61±0.55 4.16±0.96 4.10±0.44 6.62±1.52 7.06±1.51 6.70±1.34 5.61±0.70 6.75±2.55 5.47±0.60 7.95±0.78 7.75±1.33 8.09±1.12 6.17±0.33 7.04±0.32 6.54±0.52 1.37±0.72 1.53±0.54 1.39±0.44 1.09±0.30 1.40±0.55 1.62±0.57 0.28±0.06 0.30±0.06 0.26±0.06 0.18±0.02 0.28±0.03 0.20±0.04 2.19±0.96 2.81±1.28 2.29±1.19 1.76±0.68 1.98±0.63 2.44±1.25 0.51±0.14 0.65±0.27 0.40±0.18 0.34±0.05 0.49±0.10 0.42±0.07 |
Annotate: (1) administration is 4 weeks of medication, n=12; Revert to 2 weeks after the drug withdrawal, n=8.
(2) administration group and matched group compare＞0.05.
Table 15 peace palace hemostasis granules long term toxicity test histopathology changes
Experiment grouping histopathology changes
Substantial visceras such as the heart, liver, kidney, brain are not seen pathological changes, spleen all have in various degree congestion,
The high dose group lung has 3 examples to be slight interstitial pneumonia, and endocrine gland, gastrointestinal are not seen pathological changes, ovary
1-12 and in utero film growth, well-grown are not seen pathological changes
Substantial visceras such as the heart, liver, kidney, brain are not seen pathological changes, spleen all have in various degree congestion,
In dosage group lung have 4 examples to be slight interstitial pneumonia, endocrine gland, gastrointestinal not see pathological changes, ovary
13-24 reaches in utero film growth, physically well develops, and does not see pathological changes
Substantial visceras such as the matched group heart, liver, kidney, brain are not seen pathological changes, spleen all have in various degree congestion,
Lung has 4 examples to be slight interstitial pneumonia, and endocrine gland, gastrointestinal are not seen pathological changes, ovary
And in utero film is not seen pathological changes
Convalescent period PATHOMORPHOLOGICAL OBSERVATION OF PULLORUM report, similar to the administration phase basically.
From table 10～table 15 as can be known, peace palace hemostasis granules rat long term toxicity test, continuously 4 weeks of gastric infusion, two dosage groups are respectively 10gkg
-1D
-1And 5gkg
-1D
-1, normal control group equivalent distilled water.Found that body weight gain, routine blood test, hepatic and renal function, blood glucose, blood fat and internal organs system to rat all do not have obvious influence, individual data fluctuates in physiological range, no Special Significance, pathological examination, administration does not have the medicine infringement to substantial viscera, does not also cause other organ lesions.Convalescent situation is similar substantially, does not see the cumulative toxicity performance.
Can shorten blood coagulation time during administration, this is consistent with pharmacodynamics test, also cures mainly with it to match.
In sum, blood circulation promoting and blood stasis dispelling of the present invention, regulating menstruation, hemostasis.It is applied widely to cure mainly prolonged lochia, metrorrhagia, menoxenia, is applicable to big or small postpartum subinvolution of uterus, irregular the bleeding of vagina due to artificial abortion, drug induced abortion, the intrauterine device, and dysfunctional uterine bleeding.
The specific embodiment:
Embodiment 1:
Present embodiment peace palace haemostatic medicament proportioning is as follows:
Herba Leonuri 1500g
Radix Notoginseng 250g
Herba Schizonepetae charcoal 500g
Succinum 500g
Its preparation technology is:
Radix Notoginseng, succinum two flavors are ground into fine powder, and two flavors such as all the other Herba Leonuris add 10 times of water gagings and soaked 1 hour, decoct 1 hour, filter, medicinal residues add 8 times of water gagings and decoct each 1 hour 2 times, filter, merging filtrate, being concentrated into relative density is 1.08～1.10 (80 ℃), adding ethanol is 50% to containing the alcohol amount, stir evenly, standing over night filters, filtrate recycling ethanol, and be concentrated into the clear paste that relative density is 1.22～1.25 (80 ℃).Qinghuo reagent, it is an amount of to add above-mentioned medical material fine powder, binding agent 30% syrup and stevioside, and mixing is made granule, drying, packing, promptly.
Embodiment 2:
Present embodiment peace palace haemostatic medicament proportioning is as follows:
Herba Leonuri 750g
Radix Notoginseng 167g
Herba Schizonepetae charcoal 333g
Succinum 333g
Embodiment 3:
Present embodiment peace palace haemostatic medicament proportioning is as follows:
Herba Leonuri 1100g
Radix Notoginseng 205g
Herba Schizonepetae charcoal 410g
Succinum 410g
Embodiment 4:
Present embodiment peace palace haemostatic medicament proportioning is as follows:
Herba Leonuri 2000g
Radix Notoginseng 540g
Herba Schizonepetae charcoal 1080g
Succinum 1080g
Embodiment 5:
Present embodiment peace palace haemostatic medicament proportioning is as follows:
Herba Leonuri 2500g
Radix Notoginseng 833g
Herba Schizonepetae charcoal 1667g
Succinum 1667g
The preparation method of the foregoing description 2～5 peace palace haemostatic medicaments and embodiment 1 are together.
Table 7 peace palace hemostasis granules to rabbit the influence of body uterine contraction activity (X ± s, n=5)
| Dose frequency, (inferior/10min) tension force, (mn) amplitude, (mm) medicine, (gkg-1) 10min 30min 60min behind the 10min 30min 60min medicine prodrug behind the 10min 30min 60min medicine prodrug behind the medicine prodrug |
| NS 8.8±1.3 9.3±1.1 9.1±1.7 8.6±1.1 0±0 0±0.2 0±0.3 0.1±0.3 12.5±4.0 13.3±2.3 14.5±3.5 13.5±2.8 1.5 12.8±2.7 12.1±1.7 10.8±2.2 10.8±2.1 0±0 1.5±0.3* 1.3±0.3* 1.0±0.2* 16.5±5.3 19.0±5.3 17.5±7.3 16.0±6.3 3.0 10.3±1.7 10.4±1.8 9.5±2.7 9.7±2.2 0±0 1.3±0.3* 0.8±0.2* 1.5±0.3* 14.0±4.5 19.3±5.0 18.3±6.5 19.0±4.8* 0.5 11.7±2.2 10.8±2.1 9.8±2.0 9.9±2.3 0±0 3.8±1.3* 5.0±1.5* 2.2±1.1* 16.8±4.8 27.5±10.3* 29.0±12.0* 20.8±9.5。 |
Annotate: the uterine contraction baseline is designated as 0 (being that tension force is 0) before (1) administration, shows the medicine that is put to the test behind the medicine, (2) and preceding relatively * P＜0.05 of medicine
Claims (2)
1, peace palace haemostatic medicament is characterized in that being made by following raw material by weight:
Herba Leonuri 750～2500
Radix Notoginseng 167～833
Herba Schizonepetae charcoal 333～1667
Succinum 333～1667
2, peace as claimed in claim 1 palace haemostatic medicament is characterized in that being made by following raw material by weight:
Herba Leonuri 1500
Radix Notoginseng 250
Herba Schizonepetae charcoal 500
Succinum 500
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117966 CN1190228C (en) | 2003-05-30 | 2003-05-30 | Angong hemostatics |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 03117966 CN1190228C (en) | 2003-05-30 | 2003-05-30 | Angong hemostatics |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1456198A CN1456198A (en) | 2003-11-19 |
| CN1190228C true CN1190228C (en) | 2005-02-23 |
Family
ID=29411270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 03117966 Expired - Fee Related CN1190228C (en) | 2003-05-30 | 2003-05-30 | Angong hemostatics |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1190228C (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5617098B2 (en) * | 2010-06-17 | 2014-11-05 | コクヨ株式会社 | Binding tools and files |
| CN102949541A (en) * | 2012-11-08 | 2013-03-06 | 王玉青 | Traditional prescription for treating functional uterine bleeding |
| CN104547720A (en) * | 2013-11-20 | 2015-04-29 | 田孝东 | Medicament for treating functional bleeding |
| CN103550600B (en) * | 2013-11-20 | 2015-05-13 | 艾广凤 | Drug for treating dysfunctional uterine bleeding |
| CN110040720B (en) * | 2019-04-22 | 2022-05-31 | 中国科学院金属研究所 | Preparation method of high-purity narrow-diameter-distribution small-diameter double-wall carbon nano tube |
-
2003
- 2003-05-30 CN CN 03117966 patent/CN1190228C/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CN1456198A (en) | 2003-11-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1742993A (en) | Chinese patent medicine for treating gynaecologic disease and preparing method | |
| CN1233387C (en) | Chinese compound medicine for treating anhypnosis and its preparation metod | |
| CN1775276A (en) | Fushu Preparation and new preparing method | |
| CN1283291C (en) | Compound preparation for bone fracture and its preparation method | |
| CN1190228C (en) | Angong hemostatics | |
| CN1772136A (en) | Medicine composition for treating soft tissue damage and osteoarthropathy and its prepn process | |
| CN1927331A (en) | Chinese medicine preparation for curing chronic heart failure | |
| CN1478508A (en) | Chinese medicinal composition for treating fatty liver and its preparation method | |
| CN100344315C (en) | Medicinal composition for promoting bone fracture healing and its preparing method | |
| CN1559495A (en) | Deer's fetus granular Chinese madicinal preparation and its production technology | |
| CN101028325A (en) | Medicinal composition containing sailonggu, and its preparation and quality control | |
| CN1738633A (en) | Anti-obesity ingretients from medicinal plants and their composittion | |
| CN1733025A (en) | Pharmaceutical composition for treating rheumatic and rheumatoid diseases and its preparation process | |
| CN1056298C (en) | External use medicine for treating soft tissue injury and its producing method | |
| CN1562113A (en) | Medicine for treating chronic pelvic inflammation and its preparing method | |
| CN1305487C (en) | Medicinal composition for treating dysuria due to benign prostatauxe and its preparation method | |
| CN1682780A (en) | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method | |
| CN101062314A (en) | Medicine for curing gout and its preparing method | |
| CN1857627A (en) | Apoplexy treating Chinese medicine preparation and its preparing process | |
| CN1541691A (en) | Acute icterohepatitis treating Chinese traditional medicine and its preparation | |
| CN1689637A (en) | Chinese medicinal preparation for treating cardiovascular and cerebrovascular diseases and its preparing process | |
| CN1234403C (en) | Chinese medicine for treating gastric disease | |
| CN1244341C (en) | Chinese medicine composition for treating endometriosis and its prepn process | |
| CN1197611C (en) | Medicine for curing choleithiasis and preparing method thereof | |
| CN1478469A (en) | Capsule possessing antiinflammation, releaving pain and anticancer function and its preparation method |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: HEFEI KINGWIN PHARMACEUTICAL CO.,LTD. Free format text: FORMER OWNER: JIANJIANG PHARMACEUTICAL FACTORY Effective date: 20100804 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 611930 CHENGDU QIANJIANG PHARMACEUTICAL CO.,LTD, OUTER 2ND RING ROAD EAST INTERSECTION, PENGZHOU CITY, SICHUAN PROVINCE TO: 230601 HEFEI KINGWIN PHARMACEUTICAL CO.,LTD,BUILDING C, ROAD NO.D, PRIVATE SCIENCE AND TECHNOLOGY ECONOMIC PARK, ZIYUN ROAD, HEFEI ECONOMIC AND TECHNOLOGICAL DEVELOPMENT ZONE, HEFEI CITY, ANHUI PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20100804 Address after: 230601 Anhui city of Hefei province Ziyun economic and Technological Development Zone Hefei Road No. D private science and technology economic Park Road C Hefei Jinyue Pharmaceutical Co. Ltd. Patentee after: Hefei Jinyue Pharmaceutical Co., Ltd. Address before: 611930 Sichuan Province, Pengzhou City East Second Ring Road Chengdu Jianjiang pharmaceutical factory Patentee before: Jianjiang Pharmaceutical Factory |
|
| CF01 | Termination of patent right due to non-payment of annual fee | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20050223 Termination date: 20160530 |